title: Ipragliflozin , a sodium-glucose cotransporter 2 inhibitor, in the treatment of type 2 diabetes.
abstract: BACKGROUND
  Type 2 diabetes is the fastest growing non-communicable chronic disease worldwide. One of the newer treatment options is the class of sodium-glucose cotransporter 2 inhibitors that offer improved glycemia through increased urinary glucose excretion. The class has shown to be effective, safe and well-tolerated in newly diagnosed and long-standing diabetes. Additional benefits of the inhibitors include low risk of hypoglycemia and weight loss.
  
  
  METHODS
  This perspective reviews ipragliflozin - a sodium-glucose cotransporter 2 inhibitor - that has gained approval for clinical use in Type 2 diabetes in Japan. The paper discusses pharmacokinetics (PK), pharmacodynamics, clinical efficacy, safety and tolerability of the drug.
  
  
  CONCLUSIONS
  Due to its efficacy (hemoglobin A1c reduction of ≈1%), safety (low risk of hypoglycemia and very low rate of urinary tract infections), favorable PK interaction with other anti-diabetes medications and mechanism of action that is independent from β-cell function and insulin sensitivity, ipragliflozin can be used as a monotherapy or as an add-on to other agents in any stage of Type 2 diabetes.
authors: University of Maryland, Department of Medicine , 3-010A Bressler Research Building, 655 West Baltimore Street, Baltimore, MD 21201 , USA.
authors: Maka S
authors: MS
authors: Hedrington
authors: Stephen N
authors: SN
authors: Davis
mesh_terms: D003924:Diabetes Mellitus, Type 2 / Q000188:drug therapy* / Q000503:physiopathology; D004347:Drug Interactions; D005960:Glucosides / Q000009:adverse effects / Q000494:pharmacology / Q000627:therapeutic use*; D006442:Glycated Hemoglobin / Q000378:metabolism; D006801:Humans; D007003:Hypoglycemia / Q000139:chemically induced / Q000453:epidemiology; D007004:Hypoglycemic Agents / Q000009:adverse effects / Q000494:pharmacology / Q000627:therapeutic use*; D000077203:Sodium-Glucose Transporter 2 Inhibitors; D013876:Thiophenes / Q000009:adverse effects / Q000494:pharmacology / Q000627:therapeutic use*; D015431:Weight Loss / Q000187:drug effects
chemical_list: D005960:Glucosides; D006442:Glycated Hemoglobin; D007004:Hypoglycemic Agents; D000077203:Sodium-Glucose Transporter 2 Inhibitors; D013876:Thiophenes; C572941:ipragliflozin
keywords: diabetes; glucose; ipragliflozin; sodium–glucose cotransporter 2 inhibitors